How a cell deals with abnormal proteins: Pathogenetic mechanisms in protein aggregation diseases

Pathobiology

Volumn 74, Issue 3, 2007, Pages 145-158

  Aigelsreiter, A ^a   Janig, E ^a   Stumptner, C ^a   Fuchsbichler, A ^a   Zatloukal, K ^a   Denk, H ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Amyloid; Chaperones; Keratin; Mallory body; p62; Protein aggregation; Protein folding; Steatohepatitis, (non)alcoholic

Indexed keywords

CHAPERONE; CLUSTERIN; CRYSTALLIN; CYTOTOXIC FACTOR; GLUCOSE REGULATED PROTEIN 78; GLUCOSE REGULATED PROTEIN 94; HEAT SHOCK PROTEIN 110; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; PRION PROTEIN; PROTEASOME; PROTEIN; PROTEIN P62; UBIQUITIN;

ALCOHOLIC FATTY LIVER; ALPHA 1 ANTITRYPSIN DEFICIENCY; ALZHEIMER DISEASE; AMYLOIDOSIS; AMYOTROPHIC LATERAL SCLEROSIS; BIOCHEMISTRY; CHRONIC INFLAMMATION; DEGENERATIVE DISEASE; FAMILIAL MEDITERRANEAN FEVER; HEMODIALYSIS; HUMAN; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; INDIAN CHILDHOOD CIRRHOSIS; INTOXICATION; LIVER CELL CARCINOMA; MULTIPLE MYELOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PRION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEFECT; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; RHEUMATOID ARTHRITIS; THYROID MEDULLARY CARCINOMA; TUBERCULOSIS;

ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMALS; BRAIN; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; FATTY LIVER, ALCOHOLIC; HUMANS; MICE; MOLECULAR CHAPERONES; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; PROTEIN CONFORMATION; PROTEIN FOLDING;

EID: 34447633903     PISSN: 10152008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000103374     Document Type: Review

References (78)

1. Dobson CM: Principles of protein folding, misfolding and aggregation. Semin Cell Dev Biol 2004;15:3-16.
2. Dobson CM: Protein folding and misfolding. Nature 2003;426:884-890.
3. Uversky VN: Protein folding revisited. A polypeptide chain at the folding-misfolding-nonfolding cross-roads: which way to go? Cell Mol Life Sci 2003;60:1852-1871.
4. Kuznetsov G, Nigam SK: Folding of secretory and membrane proteins. N Engl J Med 1998;339:1688-1695.
5. Garcia-Mata R, Gao YS, Sztul E: Hassles with taking out the garbage: aggravating aggresomes. Traffic 2002;3:388-396.
6. Barral JM, Broadley SA, Schaffar G, Hartl FU: Roles of molecular chaperones in protein misfolding diseases. Semin Cell Dev Biol 2004;15:17-29.
7. Wickner S, Maurizi MR, Gottesman S: Post-translational quality control: folding, refolding, and degrading proteins. Science 1999;286:1888-1893.
8. Horwich A: Cell biology: sight at the end of the tunnel. Nature 2004;431:520-522.
9. Kopito RR: Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol 2000;10:524-530.
10. Shin J: P62 and the sequestosome, a novel mechanism for protein metabolism. Arch Pharm Res 1998;21:629-633.
11. Csermely P, Schnaider T, Soti C, Prohaszka Z, Nardai G: The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol Ther 1998;79:129-168.
12. Soti C, Sreedhar AS, Csermely P: Apoptosis, necrosis and cellular senescence: chaperone occupancy as a potential switch. Aging Cell 2003;2:39-45.
13. Carver JA, Rekas A, Thorn DC, Wilson MR: Small heat-shock proteins and clusterin: intra-and extracellular molecular chaperones with a common mechanism of action and function? IUBMB Life 2003;55:661-668.
14. Hayes SA, Dice JF: Roles of molecular chaperones in protein degradation. J Cell Biol 1996;132:255-258.
15. McClellan AJ, Tam S, Kaganovich D, Frydman J: Protein quality control: chaperones culling corrupt conformations. Nat Cell Biol 2005;7:736-741.
16. Sherman MY, Goldberg AL: Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 2001;29:15-32.
17. Soti C, Csermely P: Aging and molecular chaperones. Exp Gerontol 2003;38:1037-1040.
18. Mosser DD, Morimoto RI: Molecular chaperones and the stress of oncogenesis. Oncogene 2004;23:2907-2918.
19. Gregersen N, Bolund L, Bross P: Protein misfolding, aggregation, and degradation in disease. Mol Biotechnol 2005;31:141-150.
20. Poon S, Easterbrook-Smith SB, Rybchyn MS, Carver JA, Wilson MR: Clusterin is an ATP-independent chaperone with very broad substrate specificity that stabilizes stressed proteins in a folding-competent state. Biochemistry 2000;39:15953-15960.
21. Grune T, Jung T, Merker K, Davies KJ: Decreased proteolysis caused by protein aggregates, inclusion bodies, plaques, lipofuscin, ceroid, and 'aggresomes' during oxidative stress, aging, and disease. Int J Biochem Cell Biol 2004;36:2519-2530.
22. Berke SJ, Paulson HL: Protein aggregation and the ubiquitin proteasome pathway: gaining the UPPer hand on neurodegeneration. Curr Opin Genet Dev 2003;13:253-261.
23. Glickman MH: Getting in and out of the proteasome. Semin Cell Dev Biol 2000;11:149-158.
24. Pines J, Lindon C: Proteolysis: anytime, any place, anywhere? Nat Cell Biol 2005;7:731-735.
25. Elsasser S, Finley D: Delivery of ubiquitinated substrates to protein-unfolding machines. Nat Cell Biol 2005;7:742-749.
26. Goldberg AL: Protein degradation and protection against misfolded or damaged proteins. Nature 2003;426:895-899.
27. Johnston JA, Ward CL, Kopito RR: Aggresomes: a cellular response to misfolded proteins. J Cell Biol 1998;143:1883-1898.
28. Johnston JA, Illing ME, Kopito RR: Cytoplasmic dynein/dynactin mediates the assembly of aggresomes. Cell Motil Cytoskeleton 2002;53:26-38.
29. Sunde M, Blake CC: From the globular to the fibrous state: protein structure and structural conversion in amyloid formation. Q Rev Biophys 1998;31:1-39.
30. Merlini G, Bellotti V: Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583-596.
31. Carulla N, Caddy GL, Hall DR, Zurdo J, Gairi M, Feliz M, Giralt E, Robinson CV, Dobson CM: Molecular recycling within amyloid fibrils. Nature 2005;436:554-558.
32. Selkoe DJ: Folding proteins in fatal ways. Nature 2003;426:900-904.
33. Falk RH, Comenzo RL, Skinner M: The systemic amyloidoses. N Engl J Med 1997;337:898-909.
34. Bataille R, Harousseau JL: Multiple myeloma. N Engl J Med 1997;336:1657-1664.
35. Freemont AJ: The pathology of dialysis. Semin Dial 2002;15:227-231.
36. Rowland LP, Shneider NA: Amyotrophic lateral sclerosis. N Engl J Med 2001;344:1688-1700.
37. Martin JB: Molecular basis of the neurodegenerative disorders. N Engl J Med 1999;340:1970-1980.
38. Soto C: Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci 2003;4:49-60.
39. Ross CA, Poirier MA: Protein aggregation and neurodegenerative disease. Nat Med 2004;10(suppl):S10-S17.
40. Janig E, Stumptner C, Fuchsbichler A, Denk H, Zatloukal K: Interaction of stress proteins with misfolded keratins. Eur J Cell Biol 2005;84:329-339.
41. Choi-Miura NH, Oda T: Relationship between multifunctional protein 'clusterin' and Alzheimer disease. Neurobiol Aging 1996;17:717-722.
42. Selkoe DJ: Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat Cell Biol 2004;6:1054-1061.
43. Kuusisto E, Salminen A, Alafuzoff I: Early accumulation of p62 in neurofibrillary tangles in Alzheimer's disease: possible role in tangle formation. Neuropathol Appl Neurobiol 2002;28:228-237.
44. Zatloukal K, Stumptner C, Fuchsbichler A, Heid H, Schnoelzer M, Kenner L, Kleinert R, Prinz M, Aguzzi A, Denk H: p62 is a common component of cytoplasmic inclusions in protein aggregation diseases. Am J Pathol 2002;160:255-263.
45. Nakano T, Nakaso K, Nakashima K, Ohama E: Expression of ubiquitin-binding protein p62 in ubiquitin-immunoreactive intraneuronal inclusions in amyotrophic lateral sclerosis with dementia: analysis of five autopsy cases with broad clinicopathological spectrum. Acta Neuropathol (Berl) 2004;107:359-364.
46. Nagaoka U, Kim K, Jana NR, Doi H, Maruyama M, Mitsui K, Oyama F, Nukina N: Increased expression of p62 in expanded polyglutamine-expressing cells and its association with polyglutamine inclusions. J Neurochem 2004;91:57-68.
47. Kovacs GG, Puopolo M, Ladogana A, Pocchiari M, Budka H, van Duijn C, Collins SJ, Boyd A, Giulivi A, Coulthart M, Delasnerie-Laupretre N, Brandel JP, Zerr I, Kretzschmar HA, de Pedro-Cuesta J, Calero-Lara M, Glatzel M, Aguzzi A, Bishop M, Knight R, Belay G, Will R, Mitrova E: Genetic prion disease: the EUROCJD experience. Hum Genet 2005;118:166-174.
48. Aguzzi A, Miele G: Recent advances in prion biology. Curr Opin Neurol 2004;17:337-342.
49. Aguzzi A: Cell biology. Prion toxicity: all sail and no anchor. Science 2005;308:1420-1421.
50. Crowther DC, Belorgey D, Miranda E, Kinghorn KJ, Sharp LK, Lomas DA: Practical genetics: alpha-1-antitrypsin deficiency and the serpinopathies. Eur J Hum Genet 2004;12:167-172.
51. Kumar V, Cotran RS, Robbins SL: Basic Pathology, ed 7. Philadelphia, Saunders, 2002.
52. Lomas DA, Parfrey H: Alpha1-antitrypsin deficiency. 4. Molecular pathophysiology. Thorax 2004;59:529-535.
53. Parfrey H, Mahadeva R, Lomas DA: Alpha(1)-antitrypsin deficiency, liver disease and emphysema. Int J Biochem Cell Biol 2003;35:1009-1014.
54. Denk H, Stumptner C, Fuchsbichler A, Zatloukal K: Alcoholic and nonalcoholic steatohepatitis. Histopathologic and pathogenetic considerations. Pathologe 2001;22:388-398.
55. Brunt EM: Alcoholic and nonalcoholic steatohepatitis. Clin Liver Dis 2002;6:399-420, vii.
56. Brunt EM: Nonalcoholic steatohepatitis. Semin Liver Dis 2004;24:3-20.
57. Brunt EM, Tiniakos DG: Pathology of steatohepatitis. Best Pract Res Clin Gastroenterol 2002;16:691-707.
58. Stumptner C, Fuchsbichler A, Heid H, Zatloukal K, Denk H: Mallory body - a disease-associated type of sequestosome. Hepatology 2002;35:1053-1062.
59. Denk H, Gschnait F, Wolff K: Hepatocellular hyalin (Mallory bodies) in long term griseofulvin-treated mice: a new experimental model for the study of hyalin formation. Lab Invest 1975;32:773-776.
60. Tsunoo C, Harwood TR, Arak S, Yokoo H: Cytoskeletal alterations leading to Mallory body formation in livers of mice fed 3,5-diethoxycarbonyl-1,4- dihydrocollidine. J Hepatol 1987;5:85-97.
61. Kachi K, Wong PT, French SW: Molecular structural changes in Mallory body proteins in human and mouse livers: an infrared spectroscopy study. Exp Mol Pathol 1993;59:197-210.
62. Magin TM, Schröder R, Leitgeb S, Wanninger F, Zatloukal K, Grund C, Melton DW: Lessons from keratin 18 knockout mice: formation of novel keratin filaments, secondary loss of keratin 7 and accumulation of liverspecific keratin 8-positive aggregates. J Cell Biol 1998;140:1441-1451.
63. Zatloukal K, Stumptner C, Lehner M, Denk H, Baribault H, Eshkind LG, Franke WW: Cytokeratin 8 protects from hepatotoxicity, and its ratio to cytokeratin 18 determines the ability of hepatocytes to form Mallory bodies. Am J Pathol 2000;156:1263-1274.
64. Denk H, Stumptner C, Zatloukal K: Mallory bodies revisited. J Hepatol 2000;32:689-702.
65. Ku NO, Gish R, Wright TL, Omary MB: Keratin 8 mutations in patients with cryptogenic liver disease. N Engl J Med 2001;344:1580-1587.
66. Ku NO, Darling JM, Krams SM, Esquivel CO, Keeffe EB, Sibley RK, Lee YM, Wright TL, Omary MB: Keratin 8 and 18 mutations are risk factors for developing liver disease of multiple etiologies. Proc Natl Acad Sci USA 2003;100:6063-6068.
67. Ku NO, Omary MB: Keratins turn over by ubiquitination in a phosphorylation-modulated fashion. J Cell Biol 2000;149:547-552.
68. Bardag-Gorce F, Riley NE, Nan L, Montgomery RO, Li J, French BA, Lue YH, French SW: The proteasome inhibitor, PS-341, causes cytokeratin aggresome formation. Exp Mol Pathol 2004;76:9-16.
69. Heck S, Lezoualc'h F, Engert S, Behl C: Insulin-like growth factor-1-mediated neuroprotection against oxidative stress is associated with activation of nuclear factor kappaB. J Biol Chem 1999;274:9828-9835.
70. Mattson MP, Culmsee C, Yu Z, Camandola S: Roles of nuclear factor kappaB in neuronal survival and plasticity. J Neurochem 2000;74:443-456.
71. Seibenhener ML, Babu JR, Geetha T, Wong HC, Krishna NR, Wooten MW: Sequesto-some 1/p62 is a polyubiquitin chain binding protein involved in ubiquitin proteasome degradation. Mol Cell Biol 2004;24:8055-8068.
72. Denk H, Stumptner C, Fuchsbichler A, Muller T, Farr G, Muller W, Terracciano L, Zatloukal K: Are the Mallory bodies and intracellular hyaline bodies in neoplastic and non-neoplastic hepatocytes related? J Pathol 2006;208:653-661.
73. Zatloukal K, Denk H, Lackinger E, Rainer I: Hepatocellular cytokeratins as substrates of transglutaminases. Lab Invest 1989;61:603-608.
74. Zatloukal K, Fesus L, Denk H, Tarcsa E, Spurej G, Böck G: High amount of epsilon-(gamma-glutamyl)lysine cross-links in Mallory bodies. Lab Invest 1992;66:774-777.
75. Wooten MW, Hu X, Babu JR, Seibenhener ML, Geetha T, Paine MG, Wooten MC: Signaling, polyubiquitination, trafficking, and inclusions: sequestosome 1/p62's role in neurodegenerative disease. J Biomed Biotechnol 2006;2006:62079.
76. Taylor JP, Hardy J, Fischbeck KH: Toxic proteins in neurodegenerative disease. Science 2002;296:1991-1995.
77. Lansbury PT, Lashuel HA: A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 2006;443:774-779.
78. Roberson ED, Mucke L: 100 years and counting: prospects for defeating Alzheimer's disease. Science 2006;314:781-784.